For immediate release. Vancouver, British Columbia, August 4, 2023: Cannabix Technologies Inc.(CSE: BLO, OTC PINK CURRENT: BLOZF) (the “Company”)   developer of marijuana and alcohol breath testing devices reports that it has filed an International Patent Application (“PCT”) titled, “Apparatus and Methods for Capturing Non-Volatile and Semi-Volatile Substances from Breath”. This PCT application covers new innovations and intellectual property related the development to the detection of volatile organic compounds (VOCs) and Semi-Volatile Substances (like delta-9 THC) using the handheld Cannabix Breath Collection Unit (“BCU”). The BCU allows for the efficient collection, adsorption and desorption of analytes of low volatility from human breath.

Highlights and Updates:

• The Company has filed a new patent for its BCU related technology allowing for effective breath sample collection from humans for typically very difficult to detect non-volatile compounds in breath (like delta-9 THC).
• Cannabix’s Mass Spectrometer Breath Sampler (“MSBS”) technology along with BCU have been providing consistent results in the detection of delta-9 THC in breath from smoking and THC infused edibles consumption. The Company reports that early testing with Delta- 8 THC in standards, in the low 10-100 picogram range, have been detected using the MSBS technology. Delta-8 THC is present in small amounts in hemp and has psychoactive and intoxicating effects, similar though less potent compared to delta-9 THC.  Since it is extracted from legal forms of cannabis and concentrated, it has been of increasing concern for law enforcement and state governments. The Company is planning testing with metabolized delta-8 THC.
• Cannabix is advancing discussions with industry leading forensic laboratory organizations on how to best integrate its novel MSBS hardware into current forensic testing and analysis methods.
• California to usher in a new employment statute for cannabis testing that will position breath testing for cannabis as an important alternative to legacy methods.

The new PCT covers various novel methods for efficient collection of analytes of low volatility from human breath developed by the Company.  This includes liquid secondary adsorption, the concept behind the MSBS, which has repeatedly demonstrated efficient capture and release of THC. This novel method uses the breath aerosol as a carrier of solid and viscous liquid particle analytes as well as a secondary adsorbent to prevent sample loss from droplet surface contact and deposition. This is a unique capability in that current methods focus solely on volatile analytes in breath, while the non-volatile components provide much more information about the subject.  Cannabix has been continuously improving collection efficiency of the BCU, and sample transfer efficiency of the MSBS such that the results are comparable or better relative to conventional Liquid chromatography–mass spectrometry (LC-MS) forensic methods, which are time-consuming and expensive.

Breath samples collected portably with the BCU have detected and confirmed delta-9 THC in breath out to 4 hours after smoking even after being stored and analyzed up to two days after sample collection, demonstrating the robustness and utility of the method. The Company is advancing discussions with industry leading forensic laboratory organizations on how to best integrate its BCU and MSBS hardware into current forensic testing and analysis methods. Cannabix’s marijuana breath testing technologies are meeting the growing demand for new non-invasive, fairer, and more accurate delta-9 THC testing.

Significant changes in California’s employment laws have been adopted by its state legislature (known as “Assembly Bill 2188” or “AB 2188”) whereby employers in California will be prohibited from making employment decisions based upon the presence of non-psychoactive cannabis metabolites in drug screening – these are molecules that stay in a cannabis user’s system for days, weeks, or even months after use. Furthermore, employers will need to ensure that commencing January 1, 2024, they do not make any adverse employment decisions based upon an applicant’s or employee’s off-duty cannabis use (1). Cannabix’s MSBS technology has been specifically built to detect recent cannabis use – detecting Delta-9 THC, the psychoactive component of marijuana that causes impairment – using breath samples, within 1-4 hours after consumption.

Rav Mlait, CEO, commented, “We have been steadily growing and strengthening our intellectual property portfolio in the arena of breath testing — this is testament to the ability of Cannabix engineers to innovate. Our BCU and MSBS hardware continue to show very good sensitivity due to the ability to effectively collect and desorb breath samples containing non-volatiles like delta-9 THC.”

1. https://www.perkinscoie.com/en/news-insights/california-to-protect-employee-off-duty-cannabis-use-effective-2024.html

About Cannabix Technologies Inc.

Cannabix Technologies Inc. is a developer of marijuana and alcohol breathalyzer technologies for law enforcement, workplaces and laboratories. Cannabix is working to develop delta-9 THC and alcohol screening devices. Delta-9 THC is the psychoactive component of marijuana that causes impairment. Breath testing for delta-9 THC would allow employers and law enforcement to identify recent marijuana use that better aligns with impairment. Cannabix is the developer of contactless breath alcohol detection devices for employers and other settings.

We seek Safe Harbor.

On behalf of the Board of Directors

“Rav Mlait”

CEO
Cannabix Technologies Inc.

For further information, contact us by visiting https://cannabixtechnologies.com/contact/contact-us/ 

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking information that involves various risks and uncertainties regarding future events. Such forward-looking information can include without limitation statements based on current expectations involving a number of risks and uncertainties and are not guarantees of future performance of the Company, such as final development of a commercial or prototype product(s), successful trial or pilot of company technologies, no assurance that commercial sales of any kind actually materialize; no assurance the Company will have sufficient funds to complete product development. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information, including: (i) adverse market conditions; (ii) risks regarding protection of proprietary technology; (iii) the ability of the Company to complete financings; (iv) the ability of the Company to develop and market its future product; and (v) risks regarding government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition and other factors which may be identified from time to time in the Company’s public announcements and filings. There is no assurance that its development of breathalyzer technologies will provide any benefit to the Company, and no assurance that any proposed new products will be built, will be successful in beta testing or clinical trials. The is no assurance that the Company will enter into any partnerships to advance any of its corporate initiatives or technologies. There is no assurance that any “patent pending” or “provisional patents” technologies licensed by the Company or owned by the Company will receive patent status by regulatory authorities.  The Company is not currently selling commercial breathalyzers. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements.

Neither CSE nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.

Contact
For additional information on Cannabix Technologies Inc. please visit our website at https://cannabixtechnologies.com/contact/contact-us/ 

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Nextleaf Becomes First in Canada to Legally Produce THC-O

Vancouver, British Columbia–(Newsfile Corp. – June 23, 2022) – Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) (FSE: L0MA) (“Nextleaf” or the “Company“), a federally regulated manufacturer and distributor of cannabis extracts including vapes and oils, is pleased to provide an update on its Specialty Molecules division, specifically the Company’s patented novel route of manufacturing D9-tetrahydrocannabinol acetate (D9-THC-OAc, delta-9-THC-OAc, THC-OAc), colloquially referred to as THC-O (“THC-O“).

Nextleaf has recently produced THC-O under the Company’s Health Canada Research Licence in anticipation of commercialization. Nextleaf has validated its manufacturing process of THC-O through third-party analytical testing.

The Company is of the understanding that THC-O is not subject to excise tax as it does not meet the definition of “Total THC” as defined under the Excise Act 2001, which is aligned with the definition of the same in the Cannabis Act. 

In Canada, excise tax of a regulated cannabis extract is based on the amount of total delta-9-THC present. Excise tax is a critical issue in the industry, with some cannabis products manufactured with delta-9-THC subject to excise tax over 40% of the duty paid landed cost to provincial government distributors and medical cannabis distributors. 

With THC-O, Nextleaf sees potential for market disruption by marketing its novel cannabinoid ingredient as an excise tax-free alternative to delta-9-THC. Nextleaf intends to commercialize the ingredient as a therapeutic product distributed to provincial distributors and medical cannabis sales partners under the Company’s Health Canada cannabis licences.

Anecdotally, THC-O products have a more gradual onset, are longer-lasting, and have psychedelic-like effects, as compared to delta-9-THC. 

“With Nextleaf’s reputation for manufacturing standardized cannabinoid-based ingredients, and distributing Glacial Gold branded products through provincial government distributors, and pharmacies from Coast to Coast, we are excited to lead the way globally on the development of excise tax-free THC-O products manufactured within Health Canada’s regulatory framework,” said Nextleaf Co-Founder and CEO, Paul Pedersen.

Nextleaf’s patented process to manufacture THC-O enables the standardization of a more potent analog of THC. The Company holds U.S. and Canadian patents, along with a U.S. patent for a less efficient method to produce THC-O.

Since the 2018 Farm Bill was passed in the United States, unregulated hemp derived CBD is sold nationwide in the U.S., even in states that have not legalized Delta-9-THC. Because THC-O can be synthesized from hemp, the United States is seeing a surge in popularity for unregulated products marketed as hemp derived THC-O. These products are now being sold alongside the unregulated hemp derived cannabidiol (CBD) products on shelves at gas stations and corner stores throughout the United States.

Nextleaf develops cannabinoid-based vape formulations under its Health Canada Research Licence with sensory evaluation of cannabis via human testing. 

CEO Paul Pedersen joined Steve Darling from Proactive to provide more insight: https://www.youtube.com/watch?v=tTp6cyuEemw

About Nextleaf Solutions Ltd.

Nextleaf® is a federally regulated manufacturer and distributor of cannabis vapes and oils under its award-winning prohibition-era brand, Glacial Gold. The Company’s multi-patented ingredient processing technology transforms cannabis and hemp biomass into high-purity distillate at an industrial scale. Nextleaf is a low-cost producer of cannabis oils, and supplier of THC and CBD ingredients to qualified wholesale partners across Canada. Nextleaf is the first publicly traded company to be issued a U.S. patent for the industrial extraction and purification of cannabinoids. The Company has been issued 18 U.S. patents, and over 95 patents globally, on cannabinoid processing including distillation and acetylation. Nextleaf develops cannabinoid-based formulations and delivery technology through its Health Canada Research Licence with sensory evaluation of cannabis via human testing. For more information visit www.nextleafsolutions.com and www.Glacial.Gold

Nextleaf trades as OILS on the Canadian Securities Exchange, OILFF on the OTCQB Market in the United States, and L0MA on the Frankfurt Stock Exchange.

Follow the Company: Twitter, LinkedIn, Facebook, and Instagram.

Follow Glacial Gold: Instagram, Twitter, and Facebook. 

Jason McBride, Corporate Development
604-283-2301 (ext. 219)
[email protected]

On behalf of the Board of Directors of the Company,
Paul Pedersen, CEO

Certain statements contained in this press release constitute “forward-looking statements” within the meaning of applicable securities laws. All statements other than statements of historical fact contained in this press release, including, without limitation, statements regarding the Company’s anticipated delivery of its products to provincial markets across Canada and those regarding the Company’s strategy, plans, objectives, goals and targets, and any statements preceded by, followed by or that include the words “believe”, “expect”, “aim”, “intend”, “plan”, “continue”, “will”, “may”, “would”, “anticipate”, “estimate”, “forecast”, “predict”, “project”, “seek”, “should” or similar expressions or the negative thereof, are forward-looking statements. These statements are not historical facts but instead represent only the Company’s expectations, estimates and projections regarding future events. These statements are not guarantees of future performance and involve assumptions, risks and uncertainties that are difficult to predict. Therefore, actual results may differ materially from what is expressed, implied or forecasted in such forward-looking statements. Additional factors that could cause actual results, performance or achievements to differ materially include, but are not limited to the risk factors discussed in the Company’s MD&A for the most recent fiscal period. Management provides forward-looking statements because it believes they provide useful information to investors when considering their investment objectives and cautions investors not to place undue reliance on forward-looking information. Consequently, all of the forward-looking statements made in this press release are qualified by these cautionary statements and other cautionary statements or factors contained herein, and there can be no assurance that the actual results or developments will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, the Company. These forward-looking statements are made as of the date of this press release and the Company assumes no obligation to update or revise them to reflect subsequent information, events or circumstances or otherwise, except as required by law. The Canadian Securities Exchange has not reviewed or approved the contents of this press release.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

JACKSONVILLE, Fla., Aug. 16, 2021 (GLOBE NEWSWIRE) — LFTD Partners Inc., formerly known as Acquired Sales Corp. (OTCQX: AQSP) (www.AcquiredSalesCorp.com), today announced that during the second quarter of 2021 it achieved quarter-over-quarter growth in revenue of 99%, from $3,353,270 to $6,695,144, quarter-over-quarter growth in net income of 158%, from $618,359 to $1,596,154, and quarter-over-quarter growth in basic earnings per share of 75%, from $0.08 to $0.14, driven by the growth of its wholly-owned subsidiary Lifted Made (www.LiftedMade.com), maker of the award-winning Urb Finest Flowers brand of hemp-derived delta-8-THC, delta-9-THC, delta-10-THC and other emerging cannabinoid products.

Nicholas S. Warrender, Vice Chairman and COO of AQSP, and founder and CEO of Lifted Made, said: “The second quarter is a solid reflection of our foundational work over the past six months. Having moved into our new facility in Kenosha in March, we have automated production and increased capacity to meet growing demand while expanding vendor relations to reduce costs, a great challenge in this business climate. This has led to increased gross margins, allowing us to become even more competitive in the marketplace. We have relentlessly continued to expand our distribution network throughout the country. Our staff continues to expand, with an aggressive focus on revenue growth through very exciting ‘first to market’ products. I believe that between the organic growth of Lifted Made, and our planned merger with Savage Enterprises, we are well on our way toward achieving our goal of creating the most profitable and largest public company in the space.”

William C. “Jake” Jacobs, President and CFO of both AQSP and Lifted Made, said: “For the fourth straight quarter, we have proven that we are one of the few companies in the cannabis industry that can grow our revenues and profits at an extremely fast pace. Lifted currently has over $3.3 million cash in the bank. We are excited to be partnering with Savage Enterprises, a group of like-minded people, and we are looking forward to bringing other great entrepreneurs into AQSP, in a decentralized environment that doesn’t disrupt the entrepreneurs or the mojo of their companies.”

Christopher G. Wheeler, CEO of award-winning e-liquid and cannabinoid-infused products maker Savage Enterprises (www.SavageEnterprises.com) (“Savage”), Irvine, California, which has signed a letter of intent to merge into AQSP, the closing of which is subject to a number of contingencies, said, “We are super excited for the partnership with Lifted Made and AQSP. Savage Enterprises continues to grow, and is on an insane trajectory, having unaudited sales of $5.3 million in the first quarter of 2021, over $10 million in sales in the second quarter of 2021, and more than $5 million in sales in July of 2021, bringing our unaudited year to date totals to over $20 million. Our goal is to accelerate the growth and profitability of both Savage and Lifted Made.”

Matt Winters, CFO of Savage, commented, “The Savage team and I are very excited to be a part of such an explosively growing company. Savage has broken sales records month after month for the last two quarters. And, Lifted’s numbers speak for themselves. Both companies have had a phenomenal first half of the year, and we plan to finish strong. I feel that the synergy between both companies will bring both Savage and Lifted to new heights. I anticipate that we will hit sales figures in quarter four of this year that I previously thought we wouldn’t see until late next year. With both Lifted and Savage’s combined ability to market, promote, manufacture, and sell high quality hemp-derived cannabis products, I feel that we are going to continue to have this explosive growth, with a plethora of new products coming in the pipe. We are very excited and continue to work diligently on our audits and other due diligence items necessary for the closing of our merger with AQSP, while still delivering the best, highest quality, affordable, and beautifully designed products to market. Stay tuned!”

About Lifted Made and LFTD Partners Inc., Formerly Known as Acquired Sales Corp.

Lifted Made was founded in 2014 by CEO Nicholas S. Warrender. Lifted Made is a leading manufacturer of hemp and hemp-derived products. Urb Finest Flowers is Lifted Made’s flagship, award-winning brand. In February 2020, Lifted Made became a wholly-owned subsidiary of publicly traded LTFD Partners Inc., formerly known as Acquired Sales Corp. (OTCQX ticker symbol AQSP). Lifted Made’s products can be purchased online at www.LiftedMade.com.

LFTD Partners Inc., formerly known as Acquired Sales Corp. (OTCQX ticker symbol AQSP) is focused upon acquiring rapidly growing companies that manufacture and sell branded hemp-derived cannabinoid products (e.g. delta-8-THC, delta-10-THC, THCV, THCO, CBDA, CBC, CBG, CBN, CBD), e-liquid, disposable nicotine vapes, kratom and kava products. In February, 2020, AQSP acquired 100% of Warrender Enterprise Inc. d/b/a Lifted Made (formerly d/b/a Lifted Liquids) (www.LiftedMade.com), now located in Kenosha, Wisconsin. Lifted Made has a 50% membership interest in SmplyLifted LLC, which sells tobacco-free nicotine pouches under the brand name FR3SH (www.GETFR3SH.com). AQSP also owns 4.99% of CBD-infused beverage and products maker Ablis Holding Company (www.AblisBev.com), and of craft distillers Bendistillery Inc. d/b/a Crater Lake Spirits (www.CraterLakeSpirits.com) and Bend Spirits, Inc. (www.Bendistillery.com), all located in Bend, Oregon. AQSP has also signed a letter of intent to acquire delta-8-THC and CBD industry leader Savage Enterprises, and to enter the California marijuana industry by purchasing Premier Greens LLC and MKRC Holdings, LLC, the closing of which transactions are subject to a number of contingencies.

Please read AQSP’s filings with the U.S. SEC which fully describe our business and the Risk Factors associated therewith. Learn more by subscribing to our newsletters at www.LiftedMade.com and www.AcquiredSalesCorp.com.

Cautionary Note Regarding Forward-Looking Statements Certain statements in this document are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such information includes the growth and profitability strategies, and future products and plans of Lifted Made, SmplyLifted LLC, LFTD Partners Inc., formerly known as Acquired Sales Corp., Savage Enterprises and related entities. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors which may cause or contribute to the actual results of these companies’ operations or the performance or achievements of these companies differing materially from those expressed or implied by the forward-looking statements. These companies undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. Actual results, performance or achievements could differ materially from those anticipated in such forward-looking statements as a result of certain other factors, including the risk factors set forth in AQSP’s filings with the Securities and Exchange Commission.

CONTACTS:

Lifted Made
Attn: Nicholas S. Warrender, CEO
Phone: 224-577-8148
Email: [email protected]
Website: www.LiftedMade.com

LFTD Partners Inc., Formerly Known as Acquired Sales Corp.
Attn: William C. “Jake” Jacobs, President and CFO
Phone: 847-400-7660
Email: [email protected]
Website: www.AcquiredSalesCorp.com

Savage Enterprises
Attn: Brittany Warner
Phone: 714-612-1091
Email: [email protected]
Website: www.SavageEnterprises.com

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.